NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 08 04:00PM ET
3.02
Dollar change
-0.02
Percentage change
-0.66
%
Index- P/E- EPS (ttm)-5.25 Insider Own16.21% Shs Outstand15.02M Perf Week-45.59%
Market Cap45.37M Forward P/E- EPS next Y-4.27 Insider Trans0.00% Shs Float12.59M Perf Month-47.02%
Enterprise Value-0.84M PEG- EPS next Q-1.34 Inst Own73.92% Short Float12.25% Perf Quarter-20.73%
Income-78.78M P/S- EPS this Y5.54% Inst Trans-23.63% Short Ratio3.33 Perf Half Y-85.68%
Sales0.00M P/B1.07 EPS next Y7.54% ROA-85.84% Short Interest1.54M Perf YTD-85.87%
Book/sh2.81 P/C0.93 EPS next 5Y4.11% ROE-101.34% 52W High26.05 -88.41% Perf Year-86.40%
Cash/sh3.25 P/FCF- EPS past 3/5Y43.36% 54.53% ROIC-183.22% 52W Low2.27 33.33% Perf 3Y-84.35%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility23.49% 11.74% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM6.29% Oper. Margin- ATR (14)0.77 Perf 10Y-
Dividend Ex-Date- Quick Ratio4.31 Sales Y/Y TTM- Profit Margin- RSI (14)29.83 Recom1.73
Dividend Gr. 3/5Y- - Current Ratio4.31 EPS Q/Q-37.35% SMA20-44.23% Beta2.77 Target Price21.88
Payout- Debt/Eq0.06 Sales Q/Q- SMA50-42.22% Rel Volume6.16 Prev Close3.04
Employees64 LT Debt/Eq0.02 EarningsMay 12 AMC SMA200-73.17% Avg Volume463.10K Price3.02
IPOJan 10, 2020 Option/ShortYes / No EPS/Sales Surpr.-4.63% - Trades Volume2,851,621 Change-0.66%
Date Action Analyst Rating Change Price Target Change
TodayDowngrade RBC Capital Mkts Outperform → Sector Perform $5
TodayDowngrade BMO Capital Markets Outperform → Market Perform $4
Jul-07-25Downgrade William Blair Outperform → Mkt Perform
Jul-07-25Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-13-25Initiated UBS Buy $38
Dec-06-24Initiated BMO Capital Markets Outperform $63
Sep-09-24Initiated JMP Securities Mkt Outperform $70
Jul-08-24Initiated BTIG Research Buy $90
Jun-27-24Initiated Stifel Buy $86
May-06-24Initiated H.C. Wainwright Buy $65
Jul-07-25 07:30AM
Jun-14-25 10:00AM
Jun-03-25 08:00AM
May-21-25 11:23AM
May-14-25 04:30PM
04:05PM Loading…
May-12-25 04:05PM
Mar-19-25 04:21PM
Mar-01-25 12:45PM
Feb-28-25 08:00AM
Feb-27-25 08:00AM
Feb-25-25 04:30PM
Feb-10-25 08:00AM
Feb-04-25 04:30PM
Jan-08-25 07:00AM
Jan-06-25 08:00AM
04:30PM Loading…
Dec-02-24 04:30PM
Nov-13-24 04:30PM
Nov-08-24 11:28AM
Nov-07-24 07:30AM
Oct-24-24 08:00AM
Oct-23-24 08:00AM
Oct-14-24 07:00AM
Sep-10-24 07:30AM
Sep-04-24 04:30PM
Aug-13-24 07:00AM
Jun-19-24 08:00AM
Jun-17-24 04:30PM
Jun-14-24 08:00AM
May-30-24 06:05PM
May-29-24 04:30PM
01:53PM Loading…
May-14-24 01:53PM
08:00AM
May-13-24 08:00AM
May-07-24 04:30PM
12:00PM
Apr-02-24 04:30PM
Mar-22-24 08:50AM
Mar-21-24 04:30PM
Mar-19-24 08:00AM
Mar-15-24 08:00AM
Mar-14-24 12:00PM
Mar-06-24 12:53PM
08:50AM
Mar-04-24 07:30AM
Feb-26-24 04:30PM
Feb-23-24 08:00AM
Feb-19-24 08:50AM
Feb-07-24 08:00AM
Feb-06-24 08:59AM
Feb-05-24 08:00AM
Feb-02-24 08:00AM
Jan-24-24 12:14PM
Jan-05-24 08:30AM
Jan-02-24 08:00AM
Dec-18-23 04:30PM
Dec-10-23 11:00AM
Nov-30-23 08:00AM
Nov-09-23 09:48AM
08:00AM
Nov-08-23 04:30PM
Nov-02-23 09:00AM
Nov-01-23 08:00AM
Oct-09-23 08:30AM
08:00AM
Sep-25-23 08:00AM
Sep-21-23 08:00AM
Sep-15-23 08:00AM
Aug-11-23 04:05PM
Aug-04-23 04:51PM
Aug-02-23 08:00AM
Jun-22-23 08:00AM
Jun-20-23 08:00AM
Jun-13-23 08:00AM
May-12-23 04:05PM
May-10-23 08:00AM
Apr-13-23 08:00AM
Apr-10-23 04:05PM
Mar-31-23 08:00AM
Mar-23-23 08:00AM
Mar-09-23 08:00AM
Mar-08-23 04:05PM
Feb-17-23 08:20AM
08:10AM
08:00AM
Feb-16-23 04:05PM
Feb-03-23 04:05PM
Jan-30-23 08:00AM
Jan-27-23 01:10PM
Jan-25-23 08:00AM
Jan-24-23 04:25PM
Jan-13-23 08:00AM
Jan-10-23 08:00AM
Jan-04-23 08:00AM
Jan-03-23 08:00AM
Nov-10-22 04:05PM
Sep-26-22 08:00AM
Sep-23-22 08:00AM
Sep-15-22 08:00AM
Aug-12-22 04:05PM
Jun-23-22 04:05PM
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Mahal Jeetinder SinghChief Operating OfficerDec 12 '24Option Exercise7.109006,39025,909Dec 12 08:02 PM
Mahal Jeetinder SinghChief Operating OfficerDec 12 '24Sale22.1190019,89925,009Dec 12 08:02 PM
Jeetinder Singh MahalExecutive OfficerDec 12 '24Proposed Sale22.4790020,223Dec 12 08:02 PM
Mahal Jeetinder SinghChief Operating OfficerSep 12 '24Option Exercise7.109006,39025,909Sep 12 05:19 PM
Mahal Jeetinder SinghChief Operating OfficerSep 12 '24Sale21.2390019,10425,009Sep 12 05:19 PM
Jeetinder Singh MahalExecutive OfficerSep 12 '24Proposed Sale20.6690018,590Sep 12 05:18 PM